These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9680078)

  • 1. Interrelationship of cardiovascular effects, plasma levels of nicorandil, and vascular cGMP formation in conscious rats.
    Sakai K; Akima M; Kamachi S; Moriyasu M; Kitajima S
    J Pharm Pharmacol; 1998 Jun; 50(6):661-6. PubMed ID: 9680078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats.
    Sakai K; Moriyasu M; Kitajima S; Akima M; Kamachi S; Tanikawa M
    J Cardiovasc Pharmacol; 1998 Apr; 31(4):595-600. PubMed ID: 9554810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the potentiating effects of nicorandil and its denitrated metabolite (SG-86) on the adenosine-induced vasodepression in rats.
    Sakai K; Saito K
    Fundam Clin Pharmacol; 1998; 12(5):492-7. PubMed ID: 9794146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicorandil, its denitrated metabolite, SG-86 and naturally occurring vasodilators synergistically interact on adenosine-induced vasodepression in rats: special reference to adrenomedullin.
    Sakai K; Saito K
    Fundam Clin Pharmacol; 1999; 13(1):27-33. PubMed ID: 10027085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure.
    Tsutamoto T; Kinoshita M; Hisanaga T; Maeda Y; Maeda K; Wada A; Fukai D; Yoshida S
    Am J Cardiol; 1995 Jun; 75(16):1162-5. PubMed ID: 7762505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters.
    Greenberg SS; Cantor E; Ho E; Walega M
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1061-71. PubMed ID: 1679847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery.
    Fujiwara T; Angus JA
    Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular interactions characterizing the vasodilator components of nicorandil in conscious dogs.
    Humphrey SJ; Schwende FJ
    J Cardiovasc Pharmacol; 1995 Nov; 26(5):810-21. PubMed ID: 8637197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nicorandil.
    Frydman AM; Chapelle P; Diekmann H; Bruno R; Thebault JJ; Bouthier J; Caplain H; Ungethuem W; Gaillard C; Le Liboux A
    Am J Cardiol; 1989 Jun; 63(21):25J-33J. PubMed ID: 2525322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil.
    Holzmann S; Kukovetz WR; Braida C; Pöch G
    Eur J Pharmacol; 1992 Apr; 215(1):1-7. PubMed ID: 1325362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs.
    Mizumura T; Nithipatikom K; Gross GJ
    Cardiovasc Res; 1996 Aug; 32(2):274-85. PubMed ID: 8796114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-sensitive potassium-channel-opening activity of CL-065, a 3-[(substituted-carbonyl)amino]-2H-1-benzopyran, in the rat.
    Chen MJ; Lee YM; Sheu JR; Hu CT; Yen MH
    J Pharm Pharmacol; 1998 Jan; 50(1):83-90. PubMed ID: 9504439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and simple determination of nicorandil in rat plasma using a solid-phase extraction column.
    Gomita Y; Furuno K; Eto K; Fukuda T; Araki Y; Yamori M; Oishi R
    J Chromatogr; 1990 Jun; 528(2):509-16. PubMed ID: 2143508
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
    Kukovetz WR; Holzmann S
    J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S25-30. PubMed ID: 2447421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of KRN2391 with nicorandil and nifedipine on canine coronary blood flow: antagonism by glibenclamide.
    Ogawa N; Fukata Y; Kaneta S; Jinno Y; Fukushima H; Nishikori K
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):11-7. PubMed ID: 1383619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways.
    Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J
    Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic oral administration of a high dose of nicorandil on in vitro contractility of rat arterial smooth muscle.
    Trongvanichnam K; Mitsui-Saito M; Ozaki H; Karaki H
    Eur J Pharmacol; 1996 Oct; 314(1-2):83-90. PubMed ID: 8957222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of footshock stress on pharmacokinetics of nicorandil in rats.
    Yamori M; Gomita Y; Oishi R
    Life Sci; 1991; 48(21):2065-73. PubMed ID: 1827856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nicorandil on the recovery of reflex potentials after spinal cord ischaemia in cats.
    Suzuki T; Sekikawa T; Nemoto T; Moriya H; Nakaya H
    Br J Pharmacol; 1995 Sep; 116(2):1815-20. PubMed ID: 8528565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular mechanisms by which adenosine induces vasodilatation in rat skeletal muscle: significance for systemic hypoxia.
    Bryan PT; Marshall JM
    J Physiol; 1999 Jan; 514 ( Pt 1)(Pt 1):163-75. PubMed ID: 9831724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.